Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the signal transduction pathways activated by neurotrophins via their receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since the discovery of BDNF and its receptor TrkB, efforts have been made to use BDNF as a therapeutic agent for neuropsychiatric disorders or to develop small-molecule pharmaceuticals that could increase the production of BDNF or activate TrkB in brain (for review, see99,100), and these efforts are still ongoing101.”
From Neuronal plasticity and neurotrophic factors in drug responses (2017) · cites this paper as [99]
In the citing paper
“A lack of methods for effectively and safely delivering growth factors to the nervous system over sustained time periods has been a major factor limiting their translational testing32.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [32]
Citations
Cites
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“New, therapeutically interesting perspectives evolved from the observation that physical exercise evokes a marked increase in BDNF levels in the rat brain, in particular in the hippocampus and cerebral corte”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundNerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundHuang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198 · cited 1×
“For the treatment of neurons that are themselves directly involved in the formation of neuronal circuits, modified in a refined manner by neuronal activity, the local overexpression of NTs could result in functional disturbances, as for example demonstrated in the visual cortex by the local transgenic overexpression o…”
BackgroundHANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Reichlin, S. (1969) · The American Journal of The Medical Sciences · doi:10.1097/00000441-196911000-00008 · Cited by 1,134
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Bibel, M., & Barde, Y.-A. (2000) · Genes & Development · doi:10.1101/gad.841400 · Cited by 1,065
Fischer, W., Wictorin, K., Björklund, A., Williams, L. R., Varon, S., & Gage, F. H. (1987) · Nature · doi:10.1038/329065a0 · Cited by 1,024
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Anthony Altar, C., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 788 · cited 1×
“Other members of the NT family were linked to a much broader spectrum of biological action”
Background
Research works printed but not linked: 1
- Lowenstein, P.R. & Enquist, L.W. Protocols for Gene Transfer in Neuroscience (Wiley, Chichester, UK, 1996).
Cited by
Items 301–335 of 335
Kenneth, E. N., Mahapatra, S., & Hrishikesh, M. (2011) · InTech eBooks · doi:10.5772/21042 · Cited by 1
“…problems in these clinical studies, as well as corresponding animal studies, include undesirable side effects (e.g. hyperinnervation, sprouting, sympathetic stimulation, cachexia, hyperalgesia) (Apfel, 2002; Thoenen & Sendtner, 2002; Winkler et al., 1997) [reviewed in (Nagahara & Tuszynski, 2011)].”
Cell‐Specific Targeting of Fusion Proteins through Heparin Binding
Wang, J., Ma, Z., & Loeb, J. A. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch27
Motor Neuron Diseases: Molecular Mechanism, Pathophysiology, and Treatments
Sendtner, M. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400146
Self-citationNeurobiology and Treatment of Depression
Neumeister, A., Charney, D. S., Sanacora, G., & Krystal, J. H. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn018 · Cited by 1
Estudio de las vías de supervivencia y muerte neuronal en modelos de la enfermedad de Huntington
Rubia, P. P. (2010) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Demir, S. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-370
Mouse mutants and cell culture models of motoneuron disease
Sendtner, M. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.10.008
Self-citationRoles of 5HT1A receptor in CNS neurogenesis and ADAM21 in spinal cord injury.
Arnold, S. A. (2011) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/50
“This would also circumvent the peripheral side effects and low bioavailability seen with systemic administration of CNTF (Thoenen and Sendtner, 2002).”
BackgroundIntrinsic Neuronal Mechanisms in Axon Regeneration After Spinal Cord Injury
Bei, F., & He, Z. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_21
McCown, T. J. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_9 · Cited by 1
VEGF, an Angiogenic Factor with Neurotrophic Activity, Useful for Treatment of ALS?
Lambrechts, D., & Carmeliet, P. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50020-4
Physicochemical Properties for Potential Alzheimer’s Disease Drugs
Ates-Alagoz, Z., & Adejare, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00005-2
Dori, I., & Zacharaki, T. (2018) · Journal of the Hellenic Veterinary Medical Society · doi:10.12681/jhvms.14945
“Έκτοτε, πληθώρα μελετών έ χει δείξει την ευεργετική δράση των γνωστών μέχρι σήμερα νευροτροφικών παραγόντων σε πειραματικές ισχαιμικές βλάβες του εγκεφάλου (Abe 2000) και σε πρότυπα νευροεκφυλιστικών ασθενειών, όπως είναι οι νόσοι Alzheimer, Parkinson και Huntington (Alexi et al. 2000, Thoenen and…”
Dimeric Dipeptide Mimetics of Brain-Derived Neurotrophic Factor: Design and Biological Properties
Гудашева, Т. А. (2018) · Modern Approaches in Drug Designing · doi:10.31031/madd.2018.02.000541
Mechanisms Underlying Maintenance of Adult Visual Receptive Fields
Mudd, D. B. (2019) · Digital Archive @ GSU · doi:10.57709/14967304
Molecular aspects of regeneration and neuroprotection in neurodegenerative diseases
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821711-5.00007-3
D’Onofrio, P. M. (2014) · TSpace (University of Toronto)
Petruska, J. C., & Mendell, L. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.02299-9
Gloviczki, B. (2019) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10083
Multiple sclerosis: neuro-immune cross-talk in acute and progressive stages of the disease
Kerschensteiner, M., & Hohlfeld, R. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9781139195805.007 · Cited by 2
Popovich, P. G. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.728769155.793557642
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00009-4
Emerging potential neuroregenerative strategies for degenerative cervical myelopathy
Poulin, N. D., Brockie, S. T., Gengli, T., Hong, J., & Fehlings, M. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95334-4.00017-6
Neurotrophin Peptidomimetics: A new era in precision neurology and drug development
Pal, S. S., Kumar, V., ., S., ., S., Bani, K. S., & Gupta, N. (2025) · International Journal of Pharmaceutical Research and Development · doi:10.33545/26646862.2025.v7.i1f.138
Physicochemical properties for potential Alzheimer's disease drugs
Gado, S., Ateş‐Alagöz, Z., & Adejare, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00017-x
Thissen, J. (2007) · Springer eBooks · doi:10.1007/978-2-287-33475-7_15 · Cited by 2
Falangola, M. F., Voltin, J. R., Cole, M., Nietert, P., Liu, F., Iqbal, K., & Jensen, J. H. (2026) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2026.110641
Xu, T., Gan, Q., Wang, H., Liu, H., & Huang, X. (2026) · Brain and Behavior · doi:10.1002/brb3.71309
“Emerging therapies delivering CNTF or GDNF have shown potential in mitigating neuronal degeneration in other neurological conditions (Thoenen and Sendtner 2002 ), suggesting a similar applicability for shielding injured neurons in NPH.”
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation
Maini, R., Tamada, K., Fukuda, K., Takumi, T., & Suga, H. (2026) · ChemBioChem · doi:10.1002/cbic.70517
“It is clear that BDNF therapy has a huge potential in a variety of neurological disorders; however, due to short in vivo half-life, the clinical trial outcomes of using recombinant BDNF have been disappointing [12, 13].”
Patil, S. P., Kuehn, B. R., Schlosser, R., & Samohod, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.10.750759
“Despite the clear therapeutic potential of neurotrophins, their clinical application has been limited by several pharmacological challenges, including poor blood–brain barrier (BBB) permeability, short half-life, and pleiotropic effects [10,11].”
Neurotrophins as novel nutraceutical strategies for neurological complications: a review
Anamika, & Budhiraja, T. (2026) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-026-00883-y
Metadata
- Authors
- Thoenen, H., & Sendtner, M.
- Affiliations
- Max Planck Society (DE)
- University of Würzburg (DE)
- ORCID
- Sendtner, Michael
- Venue
- Nature Neuroscience
- Published
- 2002-10-28
- Volume
- 5
- Issue
- S11
- Pages
- 1046-1050
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2058026578
- Cited by
- 336
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 19 · 2018: 9 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 10 · 2013: 17 · 2012: 17
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- neurotrophins, neurotrophic factors, clinical trials, treatment failure, neurotrophin receptors, signal transduction, gene therapy
- MeSH terms
- Animals, Central Nervous System Diseases, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Humans, Nerve Growth Factors, Peripheral Nervous System Diseases, Drug Design, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.